Trial Profile
Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Givinostat (Primary)
- Indications Myeloproliferative disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Italfarmaco
- 07 Oct 2022 This trial has been completed in Germany according to European Clinical Trials Database record.
- 18 Mar 2021 According to an Italfarmaco media release, results of first interim analysis from four year mean follow-up from the study, published in Blood Cancer Journal.
- 18 Mar 2021 First interim analysis results presented in an Italfarmaco media release.